This website is fully organised and funded by Norgine Pharmaceuticals.

Angusta logo

Not a healthcare professional? Visit our public site

Contact us

An oral choice
for induction
of labour

ANGUSTA® (misoprostol 25 μg):

An approved oral misoprostol treatment for the induction of labour

Scroll image

Empowering women with the option of oral induction of labour

ANGUSTA® is an approved oral misoprostol treatment for the induction of labour1. ANGUSTA® is effective at inducing labour2 and clinical data supports the use of low dose oral misoprostol for the induction of labour3-6. ANGUSTA® has already been used for the induction of >100,000 women7.

When induction is needed, support her choice with the convenience and non-invasiveness of an oral induction.

Women prefer oral methods to vaginal ones for labour induction4,5,8

>

4

out
of

5

women who received oral misoprostol would use it again for future inductions (n=302)4

only

6

%

of women who received oral misoprostol would have preferred a Foley catheter (n=273)8

58.5

%

of women expressed a preference for an oral induction agent (n=741)5

Effective at inducing labour2–6

Previous clinical trials of oral misoprostol have shown it to be:

  • More effective than Foley catheter in an open-label, randomised controlled trial in the successful induction of a vaginal birth in 602 women with pre-eclampsia or hypertension (p=0.0136)4
  • More effective than placebo in improving PROM to delivery times in a double-blind randomised placebo controlled study in 130 patients (13.7h to 20.3h respectively p<0.05)3
  • Comparable and preferable to vaginal dinoprostone gel and Foley catheter, in previous clinical studies5,6,8

From an audit of the use of ANGUSTA® (25 µg misoprostol) in 976 women:2

85.1

%

of women had a vaginal delivery

38.8

%

of women gave birth within 24 hours

70.1

%

of women gave birth within 48 hours

WHO guidelines (2011) recommend 25 μg oral misoprostol 2-hourly as a method for induction of labour9

Pack and glass

Already used for the induction of >100,000 women7

The adverse event profile has been assessed in a compassionate use programme including >29,000 women.1

If required during labour, administration of oxytocin can start 4 hours after the last dose of ANGUSTA®.1 Breastfeeding can start 4 hours after the last dose of ANGUSTA®.1

Adverse events may include nausea, vomiting, meconium stain, postpartum haemorrhage, diarrhoea, uterine hyperstimulation, chills, pyrexia, low Apgar score and abnormal foetal heart rate.
For a full list of adverse reactions, details on precautions for use and contraindications, please refer to the ANGUSTA® Summary of Product Characteristics.

Flexible dosing

ANGUSTA® comes as ready-to-use oral tablets of 25 μg misoprostol.1 Two dosing options enable individualised treatment plans according to your hospital practice.1

The recommended maximum dose is 200 μg (8 tablets) over a period of 24 hours.1

Glass of water + 25 ug

1 tablet every 2 hours

OR

Glass of water + 50 ug

2 tablets every 4 hours

Support her personal choice and comfort with ANGUSTA®, an approved oral misoprostol for the induction of labour

REFERENCES

  1. ANGUSTA® UK Summary of Product Characteristics. September 2020.
  2. Helmig RB, Hvidman LE. Acta Obstet Gynecol Scand 2020; doi:10.1111/aogs.13876.
  3. Levy R et al. J Perinat Med 2007;35:126–129.
  4. Mundle S et al. Lancet 2017;390:669–680.
  5. Dodd JM et al. BMJ 2006;332:509–513.
  6. ten Eikelder ML et al. Lancet 2016;387:1619–1628.
  7. Data on File – Patient exposure to ANGUSTA®
  8. ten Eikelder ML et al. Am J Perinatol 2017;34:138–146.
  9. WHO recommendations for induction of labour. 2011.

Adverse events should be reported to your local regulatory agency, or in the UK Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to directly to Norgine Ltd by emailing GPharmacovigilance@norgine.com. By reporting side effects, you can help provide more information on this medicine.